FDA Approved: Pfizer’s RSV Vaccine Can Now Be Administered During Pregnancy
Abrysvo is allowed to be given to individuals who are 32-36 weeks pregnant.
FDA has approved Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.
Abrysvo is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
“Abrysvo’s approval as the first and only maternal immunization to help protect newborns immediately at birth through six months from RSV marks a significant milestone for the scientific community and for public health,” comments Annaliesa Anderson, PhD, SVP and chief scientific officer, vaccine research and development, Pfizer. “ … Today, a long-sought-after goal to deliver a maternal vaccine that will help protect infants six months of age or younger— when they are at greatest risk of possible serious consequences from RSV— has been achieved.”
How Industry Stakeholders View Medicare Advantage Expansion for Patients with Kidney Disease
July 7th 2025A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
